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further technical adjustments. Any isolate with a vancomycin MIC ~ 4 Jjg/
mI should be carefully reviewed and retested with an alternative method.
IWeP94! Prevalence of methicillin resistant Staphylococcus
aureus with reduced susceptibility to vancomydn in Belgian
h05pha~,1997-1999
C. Nonhoff, O. Denis, S. Rottiers, M. J. Struelens
National MRSA Reference Laboratory, Microbiology Dpt, Hopital Erasme,
Universite Libre de Bruxelles, Brussels, Btlgium
Objectives: To determine the prevalence of methici11in resistant S. aureus
(MRSA) with reduced susceptibility to vancomycin in two national surveys
conducted in 1997 and 1999 in Bclgian hospitals.
Methods and: results: In 1997,357 MRSA isolates from various sites were
obtained from 91 hospitals and in 1999,84 blood isolates were referred by 30
hospitals. Vancomycin susceptibility was tested by MIC determination (agar
and broth dilution, E-test with McF 0.5 and 2 inoculum on Mueller-Hinton
and Brain Heart Infusion agar, population analysis). MICs were all ~ 4 J-Iog/
ml except by high level inoculum on BHI (range 2-8 J-Iog/ml). Heterogenous
vancomycin intermediate S. aureus (hetero-VISA) with ~1O-16 subpopula-
tion growth at 4 Jjg/ml were found in 2% isolates in 1997 (9/10 from
mucocutaneous body sites) and 0% blood isolates in 1999. All hetero-VISA
isolates were c10nally related to gentamicin-resistant endemic Belgian
genotype 1.
Conduslon: Hetero-VISA are emerging at low frequency among c10nally
related MRSA strains belonging to a widespread endemic genotype in
Belgium. Improved testing methods are needed to monitor their prevalence
and assess their clinical significance.
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IWeP9SI Comparative in vitro activity of AST-n3 and eight
other antimicrobial agents against anaerobic bacteria
E. Sillerstrom, E. Wahlund, C. E. Nord
Department ofMicrobiology, Pathology and Immunology, Hut/dinge University
Hospital, Karolinska Institute, Stockholm, Sweden
Objectives: To determine the in vitro activity ofa new ketolide ABT-773
against anaerobic bacteria and compare it with that of azithromycin,
cIarithromycin, roxithromycin. erythromycin, cefoxitin, imipenem, cIin-
damycin and metronidazole.
Methods: 354 anaerobic strains isolated from clinical infections were
investigated. The antimicrobial susceptibility testing was performed by
the agar dilution method. Three control strains were used: Bacteroidesftagilis
ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741 and Clostridium
perjringens ATCC 13124.
Results: ABT-773 and imipenem were the most active antimicrobial agents
tested: Peptostreptococci (52 strains) had the following minimum inhibitory
concentrations: ABT-773, range 0.008-8.0 mg/I; imipenem, range 0.016-
0.064 mg/1. Propionibacterium acnes (32 strains): ABT-773, range 0.016-0.125
mg/I; imipenem, range 0.032-0.064 mgfl. Clostridium perftinge1ls (30 strains):
ABT-773,0.032-0.064 mg/I; imipenem, 0.016-0.5 mg/1. Clostridium difficile
(SO strains): ABT-773, 0.032-128 mg/I; imipenem, 4.0-8.0 mg/1. Bacteroides
ftagilis (100 strains): ABT-773, 0.064-8.0 mg/I; imipenem, 0.064-0.25 mgfl.
Bacteroides, Porphyromonas and Prevotella species (50 strains): ABT-773,
0.008-2.0 mg/I; imipenem, 0.016-0.25 mg/I. Fusobacteria (40 strains):
ABT-773, 0.008-4.0 mg/I; imipenem, 0.008-0.064 mg/1.
Conclusions: ABT-773 is active against anaerobic bacteria and may there-
fore be useful in the treatment and prophylaxis of anaerobic infections.
Clinical trials are therefore warranted.
IWeP96! Telithromyc1n: Comparative bacteriddal activity and
Postantibiotic Eect (PAE) against respiratory pathogens
J. Dubois·, C. St-Pierre
Novabyss Inc., Centre Universitaire de Sante de l'Estrie, Quebec, Canada
The ketolide telithromycin (HMR 3647) is an active, semisynthetic deriva-
tive of erythromycin A. The in vitro time-kill technique was performed to
assess the bactericidal activity of inhibitory concentrations of telithromycin
(HMR) with those of clarithromycin (CLA), azithromycin (AZI) and
erythromycin (ERY) against ATCC culture strains and strains recently
obtained from upper and lower respiratory tract infections including S.
pneumoniae, H. injlue1lzae, M. cata"halis, S. aureus and S. pyogenes. The PAE
was also determined with HMR and comparative agents. No bactericidal
activity was showed with HMR and other tested antibiotics against S. aureus
(penicillin-susceptible, methicillin-resistant or MLSb constitutive). Against
M. catarrhalis (/J-Iactamase positive), a bactericidal activity were only
observed with HMR and AZI. A 3 10gIO CFU/ml reduction in viable
bacteria at 2 hours was observed with S. p"eumo"iae (penicillin-susceptible,
penicillin-resistant or MLSb resistant) only by HMR. Against S. pneumoniae,
H. injluenzae and S. pyogenes, a significant PAE (> 4:00 hr) was noted with
HMR and AZI. With S. pneumoniae (penicillin-resistant or MLSb resistant),
the PAE was greater than 9 hours with HMR and most other macrolides
tested. Against S. pneumoniae, a bactericidal aetivity was observed in 4 hours
only with HMR. A significant bactericidal activity at 12 hours was noted
only by HMR and AZI against H. injluellzae (,B-laetamase positive).. The
results showed that telithromycin is an active agent with a bactericidal
activity against strains isolated from upper and lower respiratory tract
infection.
IWeP97! Activity of the ketolide AST-n3 against recent North
American isolates of Streptococcus pneumoniae
J. H.Jorgensen l , S. A. Crawford', M. L. McEimeell , C. G. Whitney2
1The University of Texas Health Science Center, Sa1l Antonio, Texas;
2Centersfor Disease Control and Prevention, Atlanta, Georgia, United States
ObjectIves: This study has examined the in vitro activity of the investiga-
tional ketolide ABT-773 (ABT) against a selected group of Streptococcus
plleumoniae isolates.
Methods: The activity of ABT was determined on 316 isolates. including
162 isolates with resistance to beta-Iactams, macrolides, Iincosamides, tetra-
cyclines, chloramphenicol, f1uoroquinolones, streptogramin or rifampin.
and ISO randomly selected susceptible isolates recovered by the CDC
Emerging Infections Program/Active Bacterial Core Surveillance system
during 1994-1998. Isolates were tested using the NCCLS reference broth
microdilution MIC method.
Results: Macrolide-susceptible strains had ABT MICs of ~0.004-0.008J1og/
ml, while macrolide-resistant strains had a wide range of ABT values from
0.008-16 J-Iog/ml. The MIC50 of ABT was 0.008 J-Iog/ml, and the MIC90 was
0.06 J-Iog/ml. Six quinupristin/dalfopristin-resistant strains had ABT MICs of
0.25-16 J-Iog/m1. Resistance to erythromycin or erythromycin/eIindamycin
resulted in varied effects on the activity on the ketolide. Of47 erythromycin-
resistant, c1indamycin-susceptible strains (efflux phenotype), 17 (36%) had
ABT MICs ~ 0.12 JIog/ml, 11/47 (23%) of the crythromycill/c1indamycin-
resistant strains (MLSB phenotype) had similarly elevated ABT MICs.
Condusions: The activity of ABT is influenced by streptogramin and, to a
lesser degree, macrolideflincosamide resistance in some pneumococcal
strains, although the mechanism of increased ABT MICs remains to be
elucidated.
IWeP9S1 Role of the C11,12-alkyllaryl carbamate extension in
the enhanced binding of the ketolide telithromydn (HMR 3647)
to bacterial ribosomes
S. Douthwaite
Odense University, Odmse, Denmark
Ketolides, a new family within the MLSB class, differ from macrolides by
replacement of the 3-c1adinose with a keto group. Telithromycin (TEL;
HMR 3647), the first ketolide, also possesses a Cll,12-aIkyl/aryl carbamate
extension. Like macrolides, ketolides interact with domains II and V of23S
rRNA, although with much higher affinity; 10-25-fold > for TEL than
erythromycin. The nature of the domain II interaction is also distinctly
different, a finding that may explain TEL's ability to bind to bacterial
ribosomes resistant to MLSB antimicrobials through domain V modifica-
tion (MLSB phenotype). This apparently specific interaction of the ketolide
Cll,12 extensions raised the possibility that these alkyl/aryl groups could
target domain II of the rRN A even in the absence of the rest of the drug
lactone ring. To test this, chemical footprintillg of compound RU72203
(structurally identical to the C11,12 extension ofTEL) was investigated in E.
coli 23S rRNA. Even at RU72203 concentrations of 1 mM (the limit that
could be kept in solution), no changes indicating specific ribosomal inter-
actions were observed at nucleotide A752 (ketolide target in domain II) or at
other nucleotides throughout the rRNA. Thus, while the Cl1,12 alkyl/aryl
COndusion: Linezolid was 6-fold more active than vancomycin against
CNS and enterococci and 100fold more active than teicoplanin against CNS.
Linezolid was 2-fold more active than teicoplanin and vancomycin against
S. aureus. Linezolid is a promising drug to treat infections caused by Gram-
positive cocci.
thromycin (ERY), ampicillin (AMP) and other antibiotics against Gram-
positive micro-organisms. Strains were isolated fromJune 1999 untilJanuary
2000 from hospitalized and non-hospitalized (only for pneumococci)
patients with clinical significant infections. 1250 strains from blood.
sputum, pus and CSF were included. MICs were obtained with the Erest.
BHI agar and an inoculum of2.0 McFarland was used for staphylococci and
enterococci (glycopeptides only) to support a better growth and clear
recognition of hetero-resistant colonies. The NCCLS method was used
for all other testing. Results are expressed as below:
VAN TEl
86 Abstracts
extension plays a key role in the enhanced ribosomal binding of TEL, this
group on its own is unable to interact with the 23S rRNA. It is possible that
ketolides such as TEL dock into domain V ofthe rRNA target guiding the
Cll,l2-alkyl/aryl extension into a position where it can make contact with
domain II.
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IWeP991/n vitro activity of Iinezolid against staphylococd
C. Cuny, W. Witte
Robert Koch Institute, Wernigerode, Branch, 38855 Wernigerode, Germany
Objective: To determine MIC profiles oflinezolid for MSSA, MRSA and
coagulase negative staphylococci.
Design: MSSA (n = 245) and MRSA (n = 58) and coagulase negative
staphylococci (n = 197) of different origin sent from all over Germany to
the national staphylococcal reference center were subjected to genomic
typing (Smal macrorcstriction pattern) and to in "itro susceptibility testing
by means 'of microbroth MIC. Mutant frequencies were determined by
plating of aliquots from broth cultures onto isosensitest agar containing 8
mg/l linezolid.
Results: MIC's for linezolid were in the range between 0.5 and 2.0 mg/I. It
was not possible to select in vitro mutants among 10111 cfu, also not for MRSA
obviously possessing mutator alleles (elevated mutant frequencies for rifs-+
rifr, tmp-s -+ tmp-r).
Conclusion: MSSA and MRSA belonging to different clonal groups of S.
aureus are sensitive to linozolid. Mutation to resistance is obviously a rare
event.
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IWeP100IA Pan-European multicentre susceptibility study
(PEMSS) of clinical isolates to llnezolid and other comparator
antibiotics
C. G. Gemmell
On behalfofcontributors to PEMSS; University ofGlasgow, United Kingdom
Medical School, Bacteriology Department
A Pan-European Multicentre Susceptibility Study tested a total of 3382
recently isolated bacterial clinical isolates which were associated with skin,
blood or respiratory tract infection. Isolates originated from France, Italy,
Germany, Spain, The Netherlands, Sweden and the United Kingdom.
Laboratories in each country independently conducted in vitro susceptibility
tests using National Committee for Clinical Laboratory Standards
(NCCLS) broth microdilution and E-test agar dilution methodology.
MIC values for each organism were determined and MIC50 and MIC90
values were calculated. The activity of Iinezolid was compared to that of
appropriate comparator agents. Linezolid demonstrated excellent activity
against all of the Gram-positive bacteria tested including methicillin-
resistant staphylococci, vancomycin-resistant enterococci and penicillin-
resistant pneumococci. Linezolid demonstrated only modest activity against
the Gram-negative respiratory tract pathogens Moraxella catarrhalis and
Haemophilus injluenzae. When the MIC data for all countries were com-
bined, the MIC50 and MIC90 values were comparable. Overall, the lowest
MIC values were obtained for isolates from Italy and the highest values were
for isolates from The Netherlands. Correlation of broth microdilutioD and
E-test MIC values indicated very similar results for vancomycin except for
VRE. Both methods indicated resistance but the MICs varied by 4-fold.
There was also little variation between MIC values for penicillin and
amoxicillin/clavulanic acid using the two methods. Linezolid E-test results
were generally lower than those obtained by the broth microdilution assay.
Overall, Iinezolid was highly active against European isolates of Gram-
positive bacteria consistent with the results of other global studies.
IWeP1011 Multi-center in vitro evaluation of Iinezolid
compared with other antibiotics in The Netherlands
A. R.Janszl,j. W. Mouton2
lpAMM Laboratory for Medical Microbiology, Veldhoven; 2Canisius
Wilhelmina Hospital, Nijmegen, Netherlands
35 Laboratories participated in a multi-ccntre study in The Netherlands to
assess the in vitro activity oflinezolid (LIN), vancomycin (VAN), teicopla-
Din (TEl), oxacillin (OXA), penicillin G (pEN), gentamicin (GEN), ery-
IWeP1 021 Susceptibility of gram-positive cocci from 25 UK
hospitals to Iinezolid and other antibiotics
C. Henwood. D. Livermore, A.Johnson, D.James. M. Warner
Linezolid Study Group; ARMRL, Colindale, London, United Kingdom
Objectives: To determine the prevalence of antibiotic resistance amongst
gram-positive cocci isolated in UK hospitals.
Methods: 25 geographically diverse UK hospitals collected consecutive,
clinically significant isolates comprising: 30 Staphylococcus aureus, 30 coagu-
lase negative staphylococci (CNS), 40 enterococci and 40 Streptoco«Us
pneumotliae. Isolates were tested using E-tests according to NCCLS criteria.
For quality control, 10% ofisolates plus those with unusual resistances were
re-tested centrally.
Results: The overall resistance rates to methicillin in S. aureus and CNS
were 19.5% and 68.9% respectively. MRSA rates in individual hospitals
ranged from 0-43.3%. Vancomycin resistance in enterococci was signifi-
cantly higher in Eltterococcus faecium (24.1 %) than E. faecalis (0.5%) (p <
0.05) with resistant isolates carrying the vanA gene. The overall resistance
rate to penicillin amongst pneumococci was 8.9%. This resistance was
predominantly intermediate resistance; with only 6 hospitals reporting
high level penicillin resistance in pneumococci. No resistance to linezolid
was found in any ofthe organisms tested; MICs for staphylococci were 0.06-
4 mg/L; for enterococci 0.12-4 mg/L and for pneumococci 0.12-4 mg/L.
Conclusions: Resistance to established antimicrobials is common in gram-
positive cocci in UK hospitals. Linezolid may prove a useful therapeutic
alternative.
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/WeP1031 Macrolide resistance in StTeptococcus pneumonlae
in Russia
T. Bogdanovitcht, L. Stratchounskil• P. Huovinen2
lSmolensk Medical Academy Smolensk, Russian Federation; 2National Public
Health Institute, Turku, Finlaltd
Objectives: To investigate the incidence and mechanisms of macrolide
resistance in clinical isolates of S. pneumoltiae
Methods: 111 clinical strains ofS. pneumoniae isolated during the 1999 were
studied. The MICs of erythromycin, azithromycin, spiramycin and cIin-
damycin were determined by the NCCLS agar dilution technique. All
erythromycin-resistant (ER) strains were further evaluated by PCR for the
presence of prm and mefgenes.
